{"title":"卵巢癌动力学蛋白超家族蛋白:从分子机制到临床应用。","authors":"Ashok Kumar Bishoyi, Shaker Al-Hasnaawei, Subbulakshmi Ganesan, Aman Shankhyan, Anima Nanda, Aashna Sinha, Subhashree Ray, Deepak Nathiya","doi":"10.1007/s12032-025-03044-1","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer remains one of the most lethal malignancies affecting women, largely due to its asymptomatic onset and frequent diagnosis at advanced stages. Emerging evidence has underscored the pivotal role of kinesin superfamily proteins (KIFs) in orchestrating the cellular mechanisms underlying tumor initiation and progression, particularly in ovarian cancer. These microtubule-associated motor proteins are essential for intracellular transport, cell division, signal transduction, and organelle positioning. Dysregulation of KIFs has been implicated in enhanced cellular proliferation, metastasis, and resistance to chemotherapy. In ovarian cancer, specific KIF members have been shown to promote cell motility and interfere with key signaling pathways, thereby accelerating tumor progression. Elevated expression levels of certain KIFs correlate with poor patient prognosis and reduced overall survival. This review consolidates current insights into the role of KIFs in ovarian cancer pathogenesis and emphasizes their potential as therapeutic targets. Elucidating the mechanistic involvement of KIFs in this malignancy may pave the way for innovative diagnostic, prognostic, and therapeutic strategies aimed at improving clinical outcomes in this highly aggressive cancer type.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 11","pages":"483"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Kinesin superfamily proteins in ovarian cancer: from molecular mechanisms to clinical applications.\",\"authors\":\"Ashok Kumar Bishoyi, Shaker Al-Hasnaawei, Subbulakshmi Ganesan, Aman Shankhyan, Anima Nanda, Aashna Sinha, Subhashree Ray, Deepak Nathiya\",\"doi\":\"10.1007/s12032-025-03044-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ovarian cancer remains one of the most lethal malignancies affecting women, largely due to its asymptomatic onset and frequent diagnosis at advanced stages. Emerging evidence has underscored the pivotal role of kinesin superfamily proteins (KIFs) in orchestrating the cellular mechanisms underlying tumor initiation and progression, particularly in ovarian cancer. These microtubule-associated motor proteins are essential for intracellular transport, cell division, signal transduction, and organelle positioning. Dysregulation of KIFs has been implicated in enhanced cellular proliferation, metastasis, and resistance to chemotherapy. In ovarian cancer, specific KIF members have been shown to promote cell motility and interfere with key signaling pathways, thereby accelerating tumor progression. Elevated expression levels of certain KIFs correlate with poor patient prognosis and reduced overall survival. This review consolidates current insights into the role of KIFs in ovarian cancer pathogenesis and emphasizes their potential as therapeutic targets. Elucidating the mechanistic involvement of KIFs in this malignancy may pave the way for innovative diagnostic, prognostic, and therapeutic strategies aimed at improving clinical outcomes in this highly aggressive cancer type.</p>\",\"PeriodicalId\":18433,\"journal\":{\"name\":\"Medical Oncology\",\"volume\":\"42 11\",\"pages\":\"483\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12032-025-03044-1\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-025-03044-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Kinesin superfamily proteins in ovarian cancer: from molecular mechanisms to clinical applications.
Ovarian cancer remains one of the most lethal malignancies affecting women, largely due to its asymptomatic onset and frequent diagnosis at advanced stages. Emerging evidence has underscored the pivotal role of kinesin superfamily proteins (KIFs) in orchestrating the cellular mechanisms underlying tumor initiation and progression, particularly in ovarian cancer. These microtubule-associated motor proteins are essential for intracellular transport, cell division, signal transduction, and organelle positioning. Dysregulation of KIFs has been implicated in enhanced cellular proliferation, metastasis, and resistance to chemotherapy. In ovarian cancer, specific KIF members have been shown to promote cell motility and interfere with key signaling pathways, thereby accelerating tumor progression. Elevated expression levels of certain KIFs correlate with poor patient prognosis and reduced overall survival. This review consolidates current insights into the role of KIFs in ovarian cancer pathogenesis and emphasizes their potential as therapeutic targets. Elucidating the mechanistic involvement of KIFs in this malignancy may pave the way for innovative diagnostic, prognostic, and therapeutic strategies aimed at improving clinical outcomes in this highly aggressive cancer type.
期刊介绍:
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.